Cargando…

SMAD1 as a biomarker and potential therapeutic target in drug-resistant multiple myeloma

BACKGROUND: SMAD1, a central mediator in TGF-β signaling, is involved in a broad range of biological activities including cell growth, apoptosis, development and immune response, and is implicated in diverse type of malignancies. Whether SMAD1 plays an important role in multiple myeloma (MM) pathoge...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Jian, Zhang, Min, Faruq, Omar, Zacksenhaus, Eldad, Chen, Wenming, Liu, Aijun, Chang, Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207655/ https://www.ncbi.nlm.nih.gov/pubmed/34134766 http://dx.doi.org/10.1186/s40364-021-00296-7

Ejemplares similares

Targeting an MDM2/MYC Axis to Overcome Drug Resistance in Multiple Myeloma
por: Faruq, Omar, et al.
Publicado: (2022)

Targeting CD47/TNFAIP8 by miR-155 overcomes drug resistance and inhibits tumor growth through induction of phagocytosis and apoptosis in multiple myeloma
por: Rastgoo, Nasrin, et al.
Publicado: (2019)

Role of Sphingolipids in Multiple Myeloma Progression, Drug Resistance, and Their Potential as Therapeutic Targets
por: Petrusca, Daniela N., et al.
Publicado: (2022)

Autophagy: A Potential Therapeutic Target to Tackle Drug Resistance in Multiple Myeloma
por: Bashiri, Hamed, et al.
Publicado: (2023)

The potential function of microRNAs as biomarkers and therapeutic targets in multiple myeloma
por: Zhu, Bingying, et al.
Publicado: (2018)

The Potential of JAG Ligands as Therapeutic Targets and Predictive Biomarkers in Multiple Myeloma
por: Platonova, Natalia, et al.
Publicado: (2023)

The vulnerability of RB loss in breast cancer: Targeting a void in cell cycle control
por: Knudsen, Erik S., et al.
Publicado: (2018)

The MODIFY Study Protocol: An Open-Label, Single-Arm, Multicenter, Prospective Pragmatic Study of Ixazomib-Based Triple-Drug Therapy in Chinese Patients with Multiple Myeloma
por: Chen, Wenming, et al.
Publicado: (2022)

Role of micro-RNAs in drug resistance of multiple myeloma
por: Abdi, Jahangir, et al.
Publicado: (2016)

Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma
por: Davis, Lorraine N., et al.
Publicado: (2021)

hsa_circ_0007841: A Novel Potential Biomarker and Drug Resistance for Multiple Myeloma
por: Gao, Meng, et al.
Publicado: (2019)

The therapeutic potential of cell cycle targeting in multiple myeloma
por: Maes, Anke, et al.
Publicado: (2017)

Circular RNA as a Novel Biomarker for Diagnosis and Prognosis and Potential Therapeutic Targets in Multiple Myeloma
por: Allegra, Alessandro, et al.
Publicado: (2022)

Overcoming drug resistance by targeting protein homeostasis in multiple myeloma
por: Moscvin, Maria, et al.
Publicado: (2021)

Novel Biomarkers and Therapeutic Targets for Melanoma
por: Sabag, Noa, et al.
Publicado: (2022)

Proteolysis targeting chimeric molecules as therapy for multiple myeloma: efficacy, biomarker and drug combinations
por: Lim, Su Lin, et al.
Publicado: (2019)

HAPLN1 confers multiple myeloma cell resistance to several classes of therapeutic drugs
por: Huynh, Mailee, et al.
Publicado: (2022)

Retrospective analysis of 264 multiple myeloma patients
por: GENG, CHUANYING, et al.
Publicado: (2013)

Clinical Significance of TP53 Abnormalities in Newly Diagnosed Multiple Myeloma
por: Ye, Fang, et al.
Publicado: (2021)

Role of epigenetics-microRNA axis in drug resistance of multiple myeloma
por: Rastgoo, Nasrin, et al.
Publicado: (2017)

Cancer drug resistance in multiple myeloma
por: Uckun, Fatih M.
Publicado: (2022)

Activation of retinoblastoma protein in mammary gland leads to ductal growth suppression, precocious differentiation, and adenocarcinoma
por: Jiang, Zhe, et al.
Publicado: (2002)

Rescue of myogenic defects in Rb-deficient cells by inhibition of autophagy or by hypoxia-induced glycolytic shift
por: Ciavarra, Giovanni, et al.
Publicado: (2010)

p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma
por: Teoh, P. J., et al.
Publicado: (2014)

Identification of potential glucocorticoid receptor therapeutic targets in multiple myeloma
por: Thomas, Alexandra L., et al.
Publicado: (2015)

Rational Targeting of Cdc42 Overcomes Drug Resistance of Multiple Myeloma
por: Nguyen, Phuong, et al.
Publicado: (2019)

The BLM helicase is a new therapeutic target in multiple myeloma involved in replication stress survival and drug resistance
por: Ovejero, Sara, et al.
Publicado: (2022)

Targeting IL-17A in Multiple Myeloma: A Potential Novel Therapeutic Approach in Myeloma
por: Prabhala, Rao H., et al.
Publicado: (2015)

Multiple myeloma with extramedullary plasmacytoma invading the skin and eyeballs following autologous stem cell transplantation: A case report
por: YANG, GUANGZHONG, et al.
Publicado: (2013)

hsa_circRNA_101237: A Novel Diagnostic and Prognostic Biomarker and Potential Therapeutic Target for Multiple Myeloma
por: Liu, Xiao, et al.
Publicado: (2020)

Progression to Metastasis of Solid Cancer
por: Zacksenhaus, Eldad, et al.
Publicado: (2021)

Molecular mechanisms in multiple myeloma drug resistance
por: Nikesitch, Nicholas, et al.
Publicado: (2016)

Novel Non-coding RNA Analysis in Multiple Myeloma Identified Through High-Throughput Sequencing
por: Lu, Minqiu, et al.
Publicado: (2021)

Drug Targeting of Genomic Instability in Multiple Myeloma
por: Beksac, Meral, et al.
Publicado: (2020)

Nucleotide excision repair is a potential therapeutic target in multiple myeloma
por: Szalat, R, et al.
Publicado: (2018)

Autophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple Myeloma
por: Al-Odat, Omar S., et al.
Publicado: (2022)

Upregulation of lncRNA NR_046683 Serves as a Prognostic Biomarker and Potential Drug Target for Multiple Myeloma
por: Dong, Hang, et al.
Publicado: (2019)

Immunotherapeutic and Targeted Approaches in Multiple Myeloma
por: Nadeem, Omar, et al.
Publicado: (2020)

Methylation data of mouse Rb-deficient pineoblastoma
por: Chung, Philip E.D., et al.
Publicado: (2020)

The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis
por: Lu, Jing, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_m99o9rdbeqpqfpusqbeugpt36i